ClinicalTrials.gov
public full text
Public Domain
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease
The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD). Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease and patient mortality.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PREVALENCE AND CHARACTERISTICS OF END-STAGE RENAL DISEASE REQUIRING HEMODIALYSIS IN JAMBI PROVINCE: IS KIDNEY TRANSPLANTATION WORTH CONSIDERING?#1039179
- Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)#982667
- Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries#919061
- Kidney Disease and Ultrasound Imaging#855323
- A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors#994207
Record · ID 830399
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive